Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study
Stock Information for Atossa Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.